The group’s CD47 x CD20 fusion protein will soon go into a Chinese phase 3.
ApexOnco Front Page
Recent articles
Tecvayli and Hernexeos might get speedy approval decisions.
And the company says it won’t need to carry out another trial.
The “next-gen” PF-07985045 is gone, but the group has another pan-KRAS shot.
And that could affect the drug's third-line accelerated approval.
A fresh licensing deal tidies up years of work between the two companies.
Furvent, in first-line EGFR exon 20 insertion lung cancer, reads out imminently.
Silevertinib trial will evaluate patients with unmethylated MGMT and EGFRvIII mutations.
